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SUMMARY
Identifying coagulation abnormalities in patients with combined bleeding and thrombosis history
is clinically challenging. Our goal was to probe the complexity of dysregulated coagulation in
humans by characterizing pathophysiologic mechanisms in a patient with both bleeding and
thrombosis. The patient is a 56-year old female with a history of hematomas, poor wound healing,
and thrombosis (retinal artery occlusion and transient cerebral ischemia). She had a normal
activated partial thromboplastin time, prolonged thrombin and reptilase times, and decreased
functional and antigenic fibrinogen levels, and was initially diagnosed with
hypodysfibrinogenemia. This diagnosis was supported by DNA analysis revealing a novel FGB
mutation (c.656A>G) predicting a Q189R mutation in the mature Bβ chain that was present in the
heterozygote state. However, turbidity analysis showed that purified fibrinogen polymerization
and degradation were indistinguishable from normal, and Bβ chain subpopulations appeared
normal by two-dimensional difference in-gel electrophoresis, indicating the mutated chain was not
secreted. Interestingly, plasma thrombin generation testing revealed the patient’s thrombin
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generation was higher than normal and could be attributed to elevated levels of factor VIII (FVIII,
163-225%). Accordingly, in an arterial injury model, hypofibrinogenemic mice (Fgn+/−) infused
with FVIII demonstrated significantly shorter vessel occlusion times than saline-infused Fgn+/−
mice. Together, these data associate the complex bleeding and thrombotic presentation with
combined hypofibrinogenemia plus plasma hypercoagulability. These findings suggest previous
cases in which fibrinogen abnormalities have been associated with thrombosis may also be
complicated by co-existing plasma hypercoagulability and illustrate the importance of “global”
coagulation testing in patients with compound presentations.
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INTRODUCTION
Identifying coagulopathies in patients with a history of both bleeding and thrombosis is
clinically challenging due to complex, interacting components during blood coagulation.
During coagulation, thrombin generation is triggered by exposure of the factor VIIa/tissue
factor (TF) complex to blood, and augmented by intrinsic tenase [activated factors IX and
VIII (FVIII)]. Low levels of certain plasma procoagulants, including factors XI, IX, VIII,
and prothrombin, cause reduced thrombin generation (1, 2) and are associated with bleeding.
In contrast, in vitro, epidemiologic, and murine studies have associated elevated levels of
these procoagulant proteins with abnormally high thrombin generation (1-3) and increased
risk of thrombosis (4-8).
The ultimate substrate in these reactions, fibrinogen, is a 340 kDa glycoprotein composed of
two copies each of three polypeptide chains (Aα, Bβ and γ) transcribed from three genes
encoding the fibrinogen Bβ (FGB), Aα (FGA), and γ (FGG) chains, ordered from
centromere to telomere, clustered in a region of approximately 50 kb on the long arm of
human chromosome 4 at 4q28-31 (9). Mature fibrinogen Aα, Bβ and γ chains are composed
of 610, 461, and 411 residues, respectively (10). Fibrinogen is synthesized and assembled in
hepatocytes as a hexameric molecule, and secreted into the bloodstream (11). During
coagulation, thrombin cleaves fibrinopeptides A and B from the N-termini of the Aα and Bβ
chains, respectively, catalyzing the conversion of fibrinogen to fibrin, which polymerizes,
stabilizes platelets, and localizes fibrinolytic enzymes (12). Fibrin can bind thrombin and
block its activity towards protein substrates; this activity is known as “antithrombin I” (13).
Fibrinogen mutations (dysfibrinogenemias) have been associated with both bleeding (14-16)
and thrombosis (16-23).
Herein, we identified a novel FGB mutation (c.656A>G) predicting a Q189R mutation in the
mature Bβ chain of a patient with a history of bleeding, thrombosis, and low functional and
antigenic fibrinogen levels, consistent with an initial diagnosis of hypodysfibrinogenemia.
However, this diagnosis was modified in light of findings that the mutant fibrinogen chain
was not present in plasma and the circulating fibrinogen molecules were functionally
normal. Interestingly, the patient demonstrated high plasma thrombin generation attributable
to elevated FVIII activity, suggesting the presence of co-existing hypercoagulability as a
cause for the thrombosis. This hypothesis was supported by a murine model of
hypofibrinogenemia (Fgn+/−) plus elevated plasma FVIII which exhibited a shorter time to
carotid artery occlusion than Fgn+/− mice infused with saline. These findings show plasma
hypercoagulability was not mitigated by low fibrinogen levels. Together, these data suggest
complex bleeding and thrombotic presentations can involve combined coagulopathies, and
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Human thrombin and corn trypsin inhibitor were from Haematologic Technologies Inc.
(Essex Junction, VT). Fibronectin-, plasminogen-, and von Willebrand factor-depleted
fibrinogen was from Enzyme Research Laboratories (South Bend, IN). Aprotinin was from
Sigma Chemical Company (St Louis, MO). Polyclonal rabbit anti-human fibrinogen
antibody was from Dako Corporation (Carpinteria, CA), and goat anti-rabbit antibodies were
from Calbiochem (La Jolla, CA) or Cappel (West Chester, PA). Mouse anti-human Bβ chain
antibody (59D8) was a kind gift from Drs. Marshall Runge and Charles Esmon, and mouse
anti-human Aα chain antibody (Y18) was a kind gift from Dr. Susan Lord. Fluorogenic
thrombin substrate (Z-Gly-Gly-Arg-AMC), TF/phospholipid reagents, and thrombin
calibrator (α2-macroglobulin/thrombin) were from Diagnostica Stago (Parsippany, NJ).
Human FVIII was from Baxter Healthcare Corporation (Glendale, CA). FVIII-deficient
plasma was from HRF (Raleigh, NC). Tissue plasminogen activator (tPA) and batroxobin
were from American Diagnostica (Greenwich, CT).
Plasma
Blood was collected through a 21-guage butterfly needle into a syringe via a protocol
approved by the University of North Carolina Institutional Review Board. The first 5 mL
were discarded. The following 30 mL were drawn into a separate syringe containing sodium
citrate/corn trypsin inhibitor (0.105 M/3.2% sodium citrate, pH 6.5, 18.3 μg/mL corn trypsin
inhibitor) to minimize contact activation (24). Platelet-free plasma was prepared by
sequential centrifugation (150×g for 15 minutes, 20,000×g for 15 minutes), aliquoted, and
snap-frozen in liquid nitrogen within 2 hours of blood collection, as described (3). Plasma
from healthy subjects was pooled for normal pooled plasma (NPP). Plasma was defibrinated
for certain experiments by incubation with batroxobin (0.5 BU/mL final, 30 minutes, 37 °C),
and removing fibrin by centrifugation (1118×g, 10 minutes, 4°C).
Sequencing
Sequencing was performed by standard Sanger sequencing (25) using primers covering all
exons and exon/intron boundaries of FGB, FGA and FGG. Polymerase chain reaction was
performed on genomic DNA. Sequencing was performed using BigDye V3.1 on an
ABI3730xl. Analysis was conducted using Sequencher V4.9 and Mutation Surveyor V3.97.
The mutation was replicated and evaluated bidirectionally. Primers and reaction conditions
are available upon request.
Fibrinogen purification
Fibrinogen was purified from the patient and normal plasmas as described (26). Briefly,
plasmas were supplemented with phenylmethanesulfonyl fluoride and benzamidine (1 mM
and 5 mM, final, respectively). Vitamin K-dependent proteins were removed by two
adsorptions against 30% BaSO4 (0.2 mL/mL plasma). Fibrinogen was precipitated twice by
glycine addition (165 mg/mL plasma), end-over-end rotation (1 hour, room temperature),
and centrifugation (4472×g, 15 minutes). SDS-PAGE and western blotting demonstrated no
fibrinogen in the supernatants of either the patient or control samples (data not shown),
indicating all fibrinogen was precipitated. Purified fibrinogen was then re-suspended and
dialyzed to 20 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (pH 7.4), 150 mM
NaCl (HBS) containing 5 KIU/mL aprotinin.
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Fibrin polymerization and fibrinolysis
Undiluted plasma was clotted with thrombin and CaCl2 (10 nM and 20 mM, final, prepared
in HBS). Purified fibrinogen (0.5 mg/mL, final) was incubated for 1 minute with CaCl2 (5
mM, final) and clotted with thrombin (5 nM, final). In both cases, fibrin polymerization was
followed by turbidity at 405 nm in a SpectraMax Plus340 spectrophotometer (Molecular
Devices, Sunnyvale, CA). The lag time was defined as the time until the initial turbidity
increased by 10 mOD units.
Tissue plasminogen activator (tPA, 0.25 μg/mL, final) was added to plasma before
triggering clot formation via addition of thrombin and CaCl2 (10 nM and 20 mM, final), as
indicated. Clot formation and lysis (turbidity increase and subsequent decrease, respectively)
were followed by turbidity at 405 nm. The fibrin lysis rate was determined as the change in
mOD versus time in the descending portion of the fibrinolysis curves.
Fibrinogen degradation
Fibrinogen (0.3 mg/mL, final) was degraded with 6 μg/mL plasmin in the presence of 1 mM
CaCl2 or 5 mM EDTA at 37 °C. Aliquots were removed at 15 and 30 minutes and 4 hours,
quenched with SDS-PAGE sample buffer, and immediately boiled. The zero time point was
performed with fibrinogen in the absence of plasmin. Samples were stored at −80 °C until
analysis by SDS-PAGE and Western blotting.
Two-dimensional difference in-gel electrophoresis (2D-DIGE)
Protein analysis by 2-Dimensional Differential In-Gel Electrophoresis (2D-DIGE) was
performed at the University of North Carolina Systems-Proteomics Center, as described
(27). Briefly, control and patient fibrinogens were labeled with Cy5- and Cy3-, respectively,
and the 2D SDS-PAGE standards with Cy2-. Individual images of Cy2-, Cy3- and Cy5-
labeled proteins were obtained using a Typhoon 9410 scanner (Amersham, Piscataway, NJ)
with excitation/emission wavelengths of 480/530 nm for Cy2-, 520/590 nm for Cy3-, and
620/680 nm for Cy5-. After imaging, gels were stained with colloidal Coomassie Blue
G-250 (BioRad, Hercules, CA). Fold differences between control and patient samples were
determined by Differential In-gel Analysis using DeCyder 2D software (version 7.0). Gel
images were calibrated in DeCyder 2D against the pI and MW of four of the known 2D
SDS-PAGE standards. The 2D gel was blotted onto polyvinylidene fluoride membrane and
probed with mouse anti-human Bβ chain (59D8), mouse anti-human fibrinogen Aα chain
(Y18), or rabbit polyclonal antibody against human fibrinogen. Membranes were stripped
between blots with 62.5 mM Tris-HCl pH 6.7, 2% SDS, and 100 mM β-mercaptoethanol.
FVIII activity measurements
Patient plasma was mixed with FVIII-deficient plasma (5% patient plasma and 95% FVIII-
deficient plasma), and clotting was initiated with Kontact reagent (33% total volume) and
calcium (10 mM, final). The clot formation rate was measured in a SpectraMax Plus340
plate reader (28) and compared to a standard curve created by mixing normal pooled plasma
(NPP) spiked with FVIII (to 150-300%) with FVIII-deficient plasma.
Thrombin generation measurements
Thrombin generation in whole and defibrinated plasma was measured by calibrated
automated thrombography (CAT) in reactions triggered with 1 pM TF/4 μM lipid and 5 pM
TF/4 μM lipid in a Fluoroskan Ascent® fluorometer (ThermoLabsystem, Helsinki, Finland),
as described (3). Thrombin generation parameters were calculated using Thrombinoscope
software version 3.0.0.29 (Thrombinoscope BV, Maastricht, Netherlands).
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Measurement of fibrinogen in mice
Fibrinogen heterozygous mice (Fgn+/−) having a deletion of the γ-chain gene have been
previously described (29). Blood was drawn from the retro-orbital plexus of Fgn+/+ and
Fgn+/− mice through heparinized capillary tubes into 30 U/mL Heparin (Sigma). Platelet-
poor plasma was prepared by centrifuging blood at 5,000×g for 10 minutes. Plasma
fibrinogen levels were measured by ELISA. Briefly, 96-well plates were coated with goat
anti-human fibrinogen antibody (Cappel) diluted 1:500 in 20 mM phosphate pH 7.4, 150
mM NaCl (PBS) for 1 hour at room temperature, washed with PBS plus 0.1% Tween-20
(PBST), and blocked with 1% BSA in PBS. Plasmas diluted serially in PBS were added to
coated plates, incubated at room temperature for two hours, and then washed with PBST.
Plates were incubated with peroxidase-conjugated goat anti-human fibrinogen antibody
(Cappel) diluted 1:25,000 in PBS with 1% BSA for one hour at room temperature, washed
in PBST, and developed with SureBlue TMB peroxidase substrate (KPL). Absorbance was
monitored at 635 nm on a SpectraMax Plus340 spectrophotometer. The rate of increase in
absorbance was fit on a semi-log plot, and the level of fibrinogen in plasma from Fgn+/−
mice was determined by comparison to Fgn+/+ mice.
Carotid artery thrombosis model
Procedures were approved by the University of North Carolina Institutional Animal Care
and Use Committee. Mice were anesthetized with 2-2.5% isoflurane in 2% oxygen, and the
left saphenous vein was exposed under a SZX12 dissecting microscope (Olympus) and
catheterized as described (30). Human FVIII or saline was administered through the catheter
on a per weight basis (blood volume [mL] is 7% of body weight [g]) 5 minutes before
injury. The endogenous FVIII concentration in mice (1 U/mL, 100%) (31) was raised by
infusion of human FVIII to levels (total murine plus human) similar to the patient’s FVIII
levels. Human FVIII binds murine vWF, has comparable cofactor activity as murine FVIII,
promotes coagulation after tail clipping and vessel injury in hemophilic mice, and has
sufficient half-life in murine circulation for these experiments (8, 32-36). The final plasma
FVIII concentration achieved in mice (198±1%) was confirmed in separate, uninjured mice
(n=2) by clotting assays, as we have described (8).
The carotid artery thrombosis model was performed as described (30). Briefly, the right
common carotid artery was exposed after midline cervical incision, dried, and treated with
10% ferric chloride (FeCl3, 0.62 M on 0.5×0.5-mm filter paper) for 2 minutes, and washed
with warm saline. Blood flow was monitored via Doppler ultrasonic flow probe (Indus
Instruments, Webster, TX). The time to occlusion (TTO) was defined as the time between
FeCl3 administration and lack of flow for 1 minute. Experiments were stopped after 40
minutes if there was no stable occlusion. Blood was drawn from the inferior vena cava
(IVC) into 3.2% sodium citrate and processed to platelet-poor plasma by centrifugation at
5000×g for 10 minutes.
Statistical analysis
Data from plasma polymerization and fibrinolysis were analyzed by non-parametric
statistics using the Wilcoxon test. Thrombin generation parameters were analyzed by
unpaired students t test. TTO data were analyzed by log-rank test (Mantel-Cox) due to
censored TTO values. P<0.05 was considered statistically significant.
RESULTS
Patient history
A 56 year-old female presented with a lifelong history of mild to moderate bleeding
including gum bleeding, spontaneous bruising, and hematoma formation. She had developed
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significant hematomas following cardiac catheterization via her brachial artery, as well as a
neck hematoma following injury with a kickboard while swimming. Additionally, she had
poor wound healing following surgery for a broken wrist and following mastectomy for
breast cancer. She also had prior thrombotic events: a left-sided central retinal artery
occlusion at age 35 and an episode of transient global amnesia thought to be ischemic at age
53, although MRI and MRA were both negative. She had no menorrhagia, and underwent 3
caesarean sections and total abdominal hysterectomy with bilateral salpingo-oophorectomy
without abnormal bleeding. She had no hyperlipidemia, diabetes, or coronary disease.
Laboratory testing revealed prolonged thrombin and reptilase times, low functional and
antigenic fibrinogen values, and prolonged platelet function analysis on two separate
occasions by PFA-100, both on and off aspirin (Table 1). The patient had elevated FVIII
activity in three separate blood draws spaced 20 months apart, but normal factor XIII
activity and von Willebrand factor antigen, activity, and multimers (Table 1). She tested
negative for prothrombin G20210A and factor V Leiden mutations, and for antiphospholipid
antibodies. The patient’s father and one of her three sons exhibited similar laboratory
fibrinogen abnormalities, but were asymptomatic. The patient’s father died following
myocardial infarction at age 65; his fibrinogen was never sequenced. The sons were
unavailable for further study.
DNA sequencing was performed only in the proband, revealing a single heterozygous A>G
base substitution in FGB at position 656, predicting a glutamine to arginine substitution at
position 189 (Q219R numbering includes the signal peptide) of the mature fibrinogen Bβ
chain. This variant was not found in the 1000 genomes catalogue of human genetic variation
(http://www.1000genomes.org/). No other mutations were found in the three fibrinogen
genes.
Plasma shows impaired clot formation and fibrinolysis
We first characterized the patient’s plasma clotting characteristics. Consistent with
prolonged thrombin and reptilase times, the formation rate and final turbidity of the patient’s
plasma clots were 1.4- and 1.6-fold lower than NPP (p<0.0001), although the lag time was
similar (Figure 1A, Table 2). When fibrinolysis was induced by adding tPA at the onset of
clotting, the decrease in turbidity was slower in the patient’s plasma than NPP (−6.7±1.0
versus −14.2±2.4 mOD/min, respectively, p<0.0001), but reached baseline at the same time
as NPP (Figure 1B).
Fibrinogen isolated from the patient’s plasma has normal composition and function
To characterize the clotting dysfunction, we then isolated fibrinogen from the patient’s
plasma and compared it to fibrinogen isolated from normal plasma. SDS-PAGE and western
blotting demonstrated no fibrinogen in the supernatant following glycine precipitation (data
not shown), indicating all fibrinogen was precipitated. Figure 2A shows purified fibrinogen
chains from the patient’s plasma separated by SDS-PAGE under reducing conditions
compared to fibrinogen purified from NPP and a commercial fibrinogen preparation.
Fibrinogen from all three sources appeared similar, with all three chains present at the
expected molecular weight. These results were confirmed by Western blot, where no
additional bands were seen in the patient sample (Figure 2B).
In contrast to findings in plasma clotting assays, clotting of the patient’s purified fibrinogen
was indistinguishable from normal fibrinogen at equal concentrations (Figure 2C, Table 2).
Furthermore, when purified patient and control fibrinogens were incubated with plasmin in
the presence of calcium or EDTA, the appearance and molecular weights of the degradation
products were identical by Coomassie Blue staining (Figure 2D) and Western blotting (data
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not shown). These findings indicate that the patient’s circulating fibrinogen, while low,
could be normally activated and degraded.
Circulating fibrinogen contains all three polypeptide chains at the expected molecular
weights and charges
Since findings with purified fibrinogen suggested the patient’s circulating fibrinogen
function was normal, we used 2D-DIGE to explicitly determine whether fibrinogen
containing the Q189R point mutation was present in the patient’s plasma. This mutation, if
present, should introduce a positive charge in the fibrinogen Bβ chain and consequently,
shift Bβ chain migration in an isoelectric field. The 2D-DIGE was performed using
ampholytes with a pI range of 3-10 and 5-8 in the first dimension; results were better
visualized in the pI range of 3-10. Cy5-labeled control and Cy3-labeled patient fibrinogens
were mixed and sequentially separated by size and charge. Figure 3 shows fluorescence
from control and patient fibrinogens individually and merged. The patient’s Bβ chains had
pIs of 6.1, 6.3, 6.4, and 6.6 (left to right), with a mass of approximately 57 kDa, similar to
control and that reported in the Expasy database (37). Western blot analysis with anti-
fibrin(ogen) antibody 59D8 (specific for the Bβ chain) confirmed the spots migrating at 57
kDa corresponded to the Bβ chains. The membrane was re-probed with anti-fibrinogen
antibody Y18 (specific for the N-terminus of the Aα chain), confirming that no degraded
Aα chain was present in the Bβ position (data not shown). These data show that fibrinogen
isolated from the patient’s plasma had a similar molecular weight and charge as control
fibrinogen, indicating the patient had hypo- but not dys-fibrinogenemia.
Patient plasma demonstrates increased thrombin generation independent of
hypofibrinogenemia
The low levels of fibrinogen and prolonged platelet function test (Table 1) provided
rationales for the patient’s bleeding tendency. However, although thrombosis in
afibrinogenemic patients may result from absence of “antithrombin I” activity (16, 38), the
patient’s fibrinogen level was ~50% of normal, making this explanation unlikely. To
determine the mechanism for the patient’s thrombotic tendency, we utilized a “global” assay
to measure plasma coagulation potential. We first triggered clotting in NPP and the patient’s
plasma with 4 μM phospholipid and 1 or 5 pM TF, and compared thrombin generation by
CAT. Interestingly, the patient’s plasma demonstrated higher thrombin generation
parameters than NPP, most strikingly with 1.5-fold increased peak thrombin when reactions
were triggered with 1 pM TF (Figure 4A, Table 3). When thrombin generation was induced
with 5 pM TF, the patient still generated more thrombin compared to NPP, but the
difference in peak thrombin was more subtle (data not shown).
We then defibrinated patient and normal plasmas and compared thrombin generation.
Similar to that seen in the presence of fibrinogen, defibrinated patient plasma exhibited 1.5-
fold higher peak thrombin than defibrinated NPP (Figure 4B, Table 3), indicating the
difference in plasma thrombin generation was not due to the difference in fibrinogen
concentration. Accordingly, adding fibrinogen to the patient plasma to reach normal levels
(330 mg/dL) further increased peak thrombin 1.4-fold over that seen in patient whole plasma
and 2-fold higher than that seen in whole NPP (data not shown). These findings suggested
the patient’s thrombosis may have resulted from a plasma hypercoagulability that was
independent of the hypofibrinogenemia.
Increased plasma thrombin generation can be attributed to elevated plasma FVIII levels
Given the patient’s increased plasma thrombin generation peak, it was of interest that she
had an elevated FVIII level in three separate blood draws spaced over 20 months (Table 1).
We previously showed that FVIII increases peak thrombin generation with little to no
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change in the lag time or time to peak (3). Therefore, we hypothesized that the increased
thrombin generation seen in the patient’s plasma was due to increased FVIII. To test this
hypothesis, we spiked FVIII (to 163, 225 and 275%, final) into defibrinated NPP and
measured thrombin generation. Raising FVIII to 225% produced similar (statistically
indistinguishable) thrombin generation in defibrinated NPP as in defibrinated patient plasma
in reactions triggered with 4 μM phospholipid and 1 pM TF (Figure 4C, Table 3, results
with 163 and 275% are not shown) or 5 pM TF (data not shown). This finding implicated
elevated FVIII in the patient’s increased plasma thrombin generation.
Elevated FVIII increases thrombosis in hypofibrinogenemic mice
We previously showed that elevated FVIII is prothrombotic in mice with normal fibrinogen
levels (8). To determine whether elevated FVIII could be prothrombotic in a background of
low fibrinogen, we used a murine model of hypofibrinogenemia (Fgn+/−) (29), expressing
39±2% (mean ± standard deviation, n=2) of the fibrinogen level of wild type (Fgn+/+)
littermates, into which we infused factor VIII or saline, as we have described (8).
Thrombosis was induced via 2-minutes application of FeCl3 to the carotid artery and the
TTO was recorded by Doppler.
Consistent with our previous findings (8), Fgn+/+ mice infused with FVIII exhibited a
shorter TTO than saline-infused Fgn+/+ mice. Furthermore, consistent with prior
observations that Fgn+/− mice have normal thrombin-induced clotting times (29), the TTO
of Fgn+/− mice infused with saline was statistically indistinguishable from wild type
(Fgn+/+) littermates (Figure 5). Importantly, Fgn+/− mice infused with FVIII (to ~200%
total, endogenous murine plus infused human protein), exhibited a significantly (p<0.05)
shorter TTO than Fgn+/− mice infused with saline (Figure 5). These data show that a low
fibrinogen level does not mitigate the prothrombotic effect of elevated plasma FVIII.
DISCUSSION
Diagnosis of patients with complex coagulopathies that include both bleeding and
thrombosis is a significant clinical challenge. Fibrinogen abnormalities have been observed
in patients with bleeding and/or thrombosis and implicated in the etiology of both
coagulopathies (14-23). To our knowledge, prior studies have not included thrombin
generation testing to rule out co-existing coagulopathies in these patients. In our patient, the
presence of a novel heterozygous mutation in the 656 A>G position in exon 4 of FGB was
consistent with the initial diagnosis of hypodysfibrinogenemia. However, this diagnosis was
modified following our findings that the mutant fibrinogen chain was not present in plasma
and the circulating fibrinogen molecules had normal functional characteristics. Further
coagulation testing revealed elevated thrombin generation in the patient’s plasma consistent
with her elevated FVIII level, as well as a shortened time to vessel occlusion in an in vivo
thrombosis model; these findings demonstrated the prothrombotic potential of this
abnormality in spite of the low fibrinogen level. Together, these data suggest a combined
etiology involving both hypofibrinogenemia and hypercoagulability.
Hypofibrinogenemia is a quantitative fibrinogen disorder characterized by reduced
coagulant activity due to low antigen levels (39). Causative mutations are divided into two
main classes: null mutations with no protein production, and mutations producing abnormal
protein chains that are retained inside the cell because of impaired hexamer assembly or
secretion (40). The most likely mechanism for the hypofibrinogenemia is a lack of secretion
due to abnormal fibrinogen assembly. Of the 403 fibrinogen molecular abnormalities
reported in the literature, 80 mutations are in the Bβ chain (41). Most FGB gene mutations
that cause hypofibrinogenemia are located in the βC domain, some of which result in Bβ
chain truncation. The present mutation, c.656 A>G (Bβ Q189R, numbering omits the signal
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peptide), is located at the end of the second half of the coiled-coil α-helical region, next to
the second disulphide ring (42), where Bβ cysteines 193 and 197 form interchain disulphide
bonds, and close to the βC domain that encompasses residues 198-461. Studies with
recombinant systems using deletion and substitution mutants indicate the coiled-coil region
and inter- and intra-chain disulphide bonds are needed to complete chain assembly (11, 43,
44). To date, the g.5157T>A (p.Leu172Gln) (45) is the only other mutation reported in exon
4 of the FGB gene; this missense mutation does not affect protein secretion, but activates a
cryptic acceptor splice site in exon 4 that results in Bβ chain truncation. Inspection of the
nucleotide sequence surrounding the present patient’s mutation suggests the mutation does
not create a typical splice site. Thus, the reason why protein containing a Bβ Q189R
mutation is not expressed is currently unknown.
It is challenging to relate thrombosis to fibrinogen abnormalities (23). Although thrombosis
in afibrinogenemic patients has been attributed to the absence of “antithrombin I” activity
(16, 38), the present patient’s fibrinogen level was ~50% of normal, making this explanation
unlikely. The patient did not carry the prothrombin G20210A or factor V Leiden mutations
or antiphospholipid antibodies; however, the thrombotic events may be at least partially
attributable to elevated FVIII levels, a common hypercoagulable state associated with
increased thrombosis risk (4-8). We previously showed that elevated FVIII increases the
thrombin generation peak height, with highest sensitivity in reactions utilizing a low TF
trigger (3). Our current data are consistent with these findings; the patient’s plasma
demonstrated a higher thrombin peak than seen in NPP, and when defibrinated NPP was
supplemented with FVIII, similar thrombin peak values were obtained as in the patient’s
defibrinated plasma (Figure 4). Importantly, we were able to recapitulate the patient’s
situation in an in vivo model of hypofibrinogenemia (Fgn+/− mice) (29) by raising FVIII to
the level present in the patient’s plasma and inducing thrombosis in the carotid artery
(Figure 5). The prothrombotic effect of elevated FVIII in Fgn+/− mice is consistent with our
prior findings in wild type mice with elevated FVIII and a normal fibrinogen level (8).
Together, these data suggest a pathogenic role for elevated FVIII in this patient.
It is of interest that Fgn+/− mice expressing ~40% fibrinogen levels had a similar TTO as
Fgn+/+ mice (Figure 5). Indeed, neither the γ chain-deleted Fgn+/− mice used in our study,
nor hemizygous Aα+/− mice expressing 75% of normal fibrinogen levels, demonstrate a
hemorrhagic phenotype or abnormal thrombin times (29, 46). The lack of bleeding in mice
with low fibrinogen levels differs from humans, who exhibit prolonged thrombin times and
mild to moderate bleeding complications with low fibrinogen.(47-51) Thus, although our
study demonstrates the utility of animal models for examining pathogenic mechanisms in
humans, the difference in phenotype in humans and mice with low fibrinogen levels
suggests additional modifiers influence clotting in these species.
Although our experiments identified likely mechanisms to explain both the bleeding and
thrombotic events, additional pathogenic mechanisms may also be present. Virchow’s Triad
suggests roles for abnormal blood composition, vascular wall function, and blood flow in the
pathogenesis of thrombosis (52). Localization of the patient’s thrombosis to the retinal artery
suggests vascular bed-specific pathology also contributes to the phenotype. Currently,
experimental means to investigate the contributions of the vessels and local shear in vivo are
not feasible. The relative contribution of the patient’s decreased platelet function to the
bleeding events is unknown. This abnormality may reflect the decreased fibrinogen levels or
stem from an alternate mechanism; we were unable to assess this aspect in the murine
model. It is also unknown whether the patient’s low fibrinogen and high FVIII levels are
related. Fibrinogen is synthesized in the liver, whereas FVIII is synthesized in the liver and
endothelium (53, 54). Both fibrinogen and FVIII levels increase during an acute phase
response. Hepatotoxicity related to failure to secrete the mutant fibrinogen chain may induce
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higher FVIII expression; however, the patient’s alanine transaminase and aspartate
aminotransferase levels were normal, suggesting normal liver function.
In conclusion, we present a novel FGB mutation, c.656 A>G, that predicts a p.Q189R
change, but is not secreted. This new hypofibrinogenemia case was confounded by a
hypercoagulable state related to elevated FVIII levels that increased plasma thrombin
generation and accelerated the time to vessel occlusion in a murine thrombosis model. To
our knowledge, this is the first characterization of combined congenital hypofibrinogenemia
and plasma hypercoagulability in a patient with bleeding and thrombosis. Thrombin
generation testing is not usually conducted in patients with suspected fibrinogen
abnormalities. Our findings suggest previous cases in which fibrinogen abnormalities have
been associated with thrombosis may also be complicated by co-existing hypercoagulability,
and therefore, warrant re-investigation.
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1. What is known on this topic
• Identifying coagulation abnormalities in patients with combined
bleeding and thrombosis history is clinically challenging.
• Abnormal levels or function of fibrinogen have been associated with
bleeding and/or thrombosis.
• Elevated factor VIII is a risk factor for thrombosis.
2. What this paper adds
• Fibrinogen containing a novel FGB mutation – c.656A>G predicting a
Q189R mutation in the mature Bβ chain – does not circulate in plasma.
• Low levels of fibrinogen (hypofibrinogenemia) do not protect against
plasma hypercoagulability.
• Global plasma testing may be necessary to understand complex
coagulopathies.
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Figure 1. Plasma demonstrates impaired clot formation and fibrinolysis
(A-B) Plasma was clotted with CaCl2 and thrombin (20 mM and 10 nM, final, respectively)
in the absence (A) and presence (B) of 0.25 μg/mL tPA. Data shown are representative of
three separate reactions performed in triplicate at room temperature and followed by
turbidity at 405 nm. Symbols are: NPP (○) and patient plasma (●).
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Figure 2. Purified fibrinogen contains all three polypeptide chains at the expected molecular
weights and has normal clotting function
A-B) Fibrinogen was precipitated from plasma, and equivalent amounts (10 μg) were
separated by 10% SDS-PAGE under reducing conditions. A) Coomassie Brilliant Blue
R250-stained gel. B) Western blot using rabbit anti-human fibrinogen polyclonal antibody.
Lanes are: (P) Patient fibrinogen, (N) Fibrinogen precipitated from NPP in-house, and (C)
Commercial fibrinogen. Molecular weight markers are indicated. C) Purified fibrinogen (0.5
mg/mL in HBS) was pre-incubated with CaCl2 (5 mM, final) for 1 minute, and clotted by
adding thrombin (5 nM, final). Panel C shows mean and standard deviation from three
separate reactions performed in triplicate at room temperature and followed by turbidity at
405 nm. Symbols are: NPP (○) and patient plasma (●); note that NPP and patient
fibrinogen polymerization curves are identical. (D) Purified fibrinogen was incubated with
plasmin in the presence of 1 mM CaCl2 or 5 mM EDTA (final, as indicated) at 37°C. Timed
aliquots were quenched with SDS-PAGE loading dye, boiled, separated by non-reducing
4-12% SDS-PAGE, and stained by Coomassie Brilliant Blue R250.
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Figure 3. No abnormal fibrinogen is detected in the patient plasma by 2D-DIGE
Control and patient samples and SDS-PAGE standards were labeled with Cy5-, Cy3-, and
Cy2-, respectively, and separated by 2D-DIGE. Individual images of labeled proteins were
obtained using a Typhoon 9410 scanner and compared using DeCyder 2D software (v7.0).
Top to bottom: Control and patient samples individually, superimposed images of control
and patient, and western blot of the 2D-DIGE using anti-human Bβ chain antibody (59D8).
The Bβ chain pIs are indicated in the patient image.
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Figure 4. Whole and defibrinated patient plasmas demonstrate abnormal thrombin generation
that can be recapitulated by raising the FVIII level in NPP
Thrombin generation was initiated by adding 4 μM phospholipid and 1 pM TF to whole (A)
or defibrinated (B, C) plasmas. CAT detects higher thrombin generation in the presence of
fibrinogen than in its absence because fibrin-bound thrombin is protected from inhibition by
antithrombin III but can still cleave fluorogenic substrate (3, 56, 57). A, B) Symbols are:
NPP (○), patient plasma (●). C) Thrombin generation was initiated by adding 4 μM
phospholipid and 1 pM TF to defibrinated NPP (○), defibrinated patient plasma (●), and
defibrinated NPP plus FVIII (✞, 225%, final). Data show mean and standard deviations from
experiments performed in triplicate in three independent assays for whole plasmas, and in
triplicate in two to five independent assays for defibrinated plasmas.
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Figure 5. Elevated FVIII shortens the TTO after FeCl3 injury to the carotid artery of Fgn
+/−
mice
Fgn+/+ and Fgn+/− mice were infused with saline or FVIII to 198±1% of normal.
Thrombosis was induced by application of 10% FeCl3 to the carotid artery for 2 minutes,
and the TTO was determined by Doppler. In vessels that did not occlude, the TTO was
censored at 40 minutes. Each point represents a separate mouse. Lines show median values.
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Table 1
Summary of screening tests
Coagulation Tests Normal range Patient
a
aPTT (sec) 25.2 – 36.2 29.6, 31.9
Prothrombin Time (sec) 10.1 – 12.6 11.9, 12.2
Thrombin Time (sec) 13.4 – 18.0 18.2, 22.6
Reptilase Time (sec) 15.0 – 19.2 21.3
Functional fibrinogen (Clauss, mg/dL) 208 – 409 162
Fibrinogen antigen (mg/dL) 150 – 375 148
Functional fibrinogen (clot weight(55), mg/dL)
330
b 170
von Willebrand factor antigen (% of normal) 56 – 223 147
von Willebrand factor activity (% of normal) 50 – 204 140
FVIII activity in blood draw 1 (% of normal) 54 – 161 163
FVIII activity in blood draw 2 (% of normal)
100
c 225
FVIII activity in blood draw 3 (% of normal)
100
c 225
Antithrombin III (% of normal) 88 – 133 97
PFA-100: collagen and epinephrine (sec) 84 – 178
>300, 132
d




alanine transaminase (U/L) 15 – 48 24, 25, 22
aspartate aminotransferase (U/L) 14 – 38 25, 21, 27
Cholesterol (mg/dL) 100 – 199 220, 251, 192
Triglycerides (mg/dL) 1 – 149 55, 85, 54
a
Multiple values are from separate blood draws
b
Fibrinogen concentration in NPP
c
FVIII activity in NPP
d
First PFA-100 was on aspirin, second was off aspirin for 2 weeks













Marchi et al. Page 23
Table 2
Summary of plasma and purified fibrin polymerization parameters
NPP Patient
Plasma Clotting Parameters 
a
Onset (min)
b 0.2 ± 0.1 0.3 ± 0.1
Rate (Vmax, mOD/min) 292 ± 52 202 ± 35*
Turbidity change (mOD) 612 ± 19 374 ± 18*
Purified Fibrinogen Clotting Parameters 
a
Onset (min)
b 0.9 ± 0.2 0.9 ± 0.4
Rate (Vmax, mOD/min) 67 ± 20 70 ± 22
Turbidity change (mOD) 142 ± 8 143 ± 16
a
Mean ± standard deviation from three independent experiments from two separate blood draws, performed in triplicate
b
Time until turbidity increased 10 mOD units
*
p< 0.0001 versus NPP
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